Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CytomX Therapeutics, Inc. (CTMX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/08/2023 8-K Quarterly results
Docs: "CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - CX-904 initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 and CX-801 anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., August 8, 2023 –"
06/30/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Pre-Funded Warrant",
"Form of Tranche Warrant",
"Unit Purchase Agreement by and among the Company and the Purchasers"
05/09/2023 8-K Quarterly results
Docs: "CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Continued progress in Phase 1 dose escalation for CX-904 - - IND enabling activities on track for filings for CX-2051 and CX-801 in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1 to Phase 2 clinical evaluation as lead, next-generation CTLA-4 program - - CD71strategy under evaluation including potential further advancement of CX-2029 and next generation CD71 targeting strategies - - Continued progress in strategic alliances including a $5 million clinical candidate milestone in Probody® T-Cell Bispecific collaboration with Astellas and initiation of Regeneron and Moderna collaborations - - Marcia Belvin, Ph.D. promoted to C..."
03/27/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/24/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
01/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/21/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/08/2022 8-K Quarterly results
09/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
09/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/04/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update - Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer reported in 2021 - - First-in-human study of CX-904 in advanced solid tumors to be initiated in first half of 2022 - - Initial data for Arms A and B in Phase 2 study of praluzatamab ravtansine in breast cancer expected in second half of 2022 - SOUTH SAN FRANCISCO, Calif., March 1, 2022 –"
02/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/07/2022 8-K Quarterly results
01/10/2022 8-K Investor presentation
Docs: "© 2022 CytomX Therapeutics, Inc. 40 th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman January 12, 2022"
11/04/2021 8-K Quarterly results
Docs: "CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab ravtansine expected in 2022- SOUTH SAN FRANCISCO, Calif., November 4, 2021 –"
10/04/2021 8-K Appointed a new director
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/25/2021 8-K Asset disposition
Docs: "Underwriting Agreement, among CytomX Therapeutics, Inc. and J.P Morgan securities LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the underwriters named therein",
"Opinion of Latham & Watkins LLP"
01/19/2021 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
12/22/2020 8-K Appointed a new director
11/05/2020 8-K Quarterly results
Docs: "- Q3-20 EARNINGS RELEASE"
10/06/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy